# OnCo record retifanlimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/retifanlimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "retifanlimab" ;
  schema:name "Retifanlimab"@en ;
  schema:description "Retifanlimab is a PD-1 antibody approved for Merkel cell carcinoma and, with chemotherapy, as the first immunotherapy standard for advanced anal cancer."@en ;
  schema:url <https://onco.cc/drugs/retifanlimab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Retifanlimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q117349369> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(25)00631-2>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=retifanlimab> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Anti-PD-1 monoclonal antibody (IgG4)" ;
  schema:alternateName "Zynyz" ;
  onco:approval "US 2023: Metastatic or recurrent locally advanced Merkel cell carcinoma", "US 2025: Locally recurrent or metastatic anal SCC with carboplatin-paclitaxel; monotherapy after platinum", "EU 2024: Merkel cell carcinoma" ;
  onco:acceleratedApproval "US 2023-03-22: Adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)" ;
  onco:acceleratedApprovalConfirmed "US 2025-12-17: Adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)" ;
  onco:cancers <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/metastatic-anal-cancer/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:trials <https://onco.cc/trials/nct05287113/>, <https://onco.cc/trials/nct06072612/>, <https://onco.cc/trials/pod1um-201/> .